Angiotensin II in Vasodilatory Shock

被引：10
|
作者：
Wakefield, Brett J. [1 ,2 ]
Busse, Laurence W. [3 ]
Khanna, Ashish K. [1 ,4 ,5 ]
机构：
[1] Cleveland Clin, Dept Gen Anesthesiol, Anesthesiol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Washington Univ, Div Crit Care Med, Dept Anesthesiol, Sch Med, 660 South Euclid Ave,Campus Box 8054, St Louis, MO 63110 USA
[3] Emory Univ, Emory St Josephs Hosp, Div Pulm Crit Care Allergy & Sleep Med, Sch Med, 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 USA
[4] Cleveland Clin, Dept Outcomes Res, Ctr Crit Care, 9500 Euclid Ave,G58, Cleveland, OH 44195 USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27109 USA
来源：
CRITICAL CARE CLINICS | 2019年 / 35卷 / 02期
关键词：
Vasodilatory shock; Septic shock; Angiotensin II; Vasopressor; Blood pressure; MEAN ARTERIAL-PRESSURE; SEPTIC SHOCK; ARGININE-VASOPRESSIN; CLINICAL-EXPERIENCE; ALDOSTERONE SYSTEM; CONVERTING-ENZYME; RENIN; NOREPINEPHRINE; MANAGEMENT; RECEPTORS;
D O I：
10.1016/j.ccc.2018.11.003
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholamine-sparing properties of angiotensin II. As a result, the Food and Drug Administration has approved angiotensin II for the treatment of vasodilatory shock. This review details the goals of treatment of vasodilatory shock in addition to the history, current use, and recent research regarding the use of angiotensin II. An illustrative case of the use of angiotensin II is also incorporated for understanding the clinical utility of the drug.
引用
收藏
页码：229 / +
页数：18
相关论文
共 50 条
  • [1] Roles of angiotensin II as vasopressor in vasodilatory shock
    Lumlertgul, Nuttha
    Ostermann, Marlies
    FUTURE CARDIOLOGY, 2020, 16 (06) : 569 - 584
  • [2] Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies
    Heavner, Mojdeh S.
    McCurdy, Michael T.
    Mazzeffi, Michael A.
    Galvagno, Samuel M., Jr.
    Tanaka, Kenichi A.
    Chow, Jonathan H.
    JOURNAL OF INTENSIVE CARE MEDICINE, 2021, 36 (06) : 635 - 645
  • [3] Vasodilatory shock in the ICU and the role of angiotensin II
    Wakefield, Brett J.
    Sacha, Gretchen L.
    Khanna, Ashish K.
    CURRENT OPINION IN CRITICAL CARE, 2018, 24 (04) : 277 - 285
  • [4] Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
    Bellomo, Rinaldo
    Wunderink, Richard G.
    Szerlip, Harold
    English, Shane W.
    Busse, Laurence W.
    Deane, Adam M.
    Khanna, Ashish K.
    McCurdy, Michael T.
    Ostermann, Marlies
    Young, Paul J.
    Handisides, Damian R.
    Chawla, Lakhmir S.
    Tidmarsh, George F.
    Albertson, Timothy E.
    CRITICAL CARE, 2020, 24 (01):
  • [5] Angiotensin II for the Treatment of Vasodilatory Shock
    Khanna, Ashish
    English, Shane W.
    Wang, Xueyuan S.
    Ham, Kealy
    Tumlin, James
    Szerlip, Harold
    Busse, Laurence W.
    Altaweel, Laith
    Albertson, Timothy E.
    Mackey, Caleb
    McCurdy, Michael T.
    Boldt, David W.
    Chock, Stefan
    Young, Paul J.
    Krell, Kenneth
    Wunderink, Richard G.
    Ostermann, Marlies
    Murugan, Raghavan
    Gong, Michelle N.
    Panwar, Rakshit
    Hastbacka, Johanna
    Favory, Raphael
    Venkatesh, Balasubramanian
    Thompson, B. Taylor
    Bellomo, Rinaldo
    Jensen, Jeffrey
    Kroll, Stew
    Chawla, Lakhmir S.
    Tidmarsh, George F.
    Deane, Adam M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05) : 419 - 430
  • [6] Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin
    Rodriguez, Ryan
    Cucci, Michaelia
    Kane, Sean
    Fernandez, Erica
    Benken, Scott
    JOURNAL OF INTENSIVE CARE MEDICINE, 2020, 35 (04) : 327 - 337
  • [7] Angiotensin II : a new therapeutic option for vasodilatory shock
    Bussard, Rachel L.
    Busse, Laurence W.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1287 - 1298
  • [8] A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock
    Bissell, Brittany D.
    Browder, Kelsey
    McKenzie, Matt
    Flannery, Alexander H.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (09) : 920 - 927
  • [9] Angiotensin II (Giapreza): A Distinct Mechanism for the Treatment of Vasodilatory Shock
    Khalique, Saira C.
    Ferguson, Nadia
    CARDIOLOGY IN REVIEW, 2019, 27 (03) : 167 - 169
  • [10] Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data
    Abril, Maria K.
    Khanna, Ashish K.
    Kroll, Stew
    McNamara, Connor
    Handisides, Damian
    Busse, Laurence W.
    JOURNAL OF CRITICAL CARE, 2019, 50 : 188 - 194
12345